You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Dow
Johnson and Johnson
Baxter
Mallinckrodt
McKinsey

Last Updated: May 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LOMUSTINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lomustine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002569 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed Eastern Cooperative Oncology Group Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
NCT00002569 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed National Cancer Institute (NCI) Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
NCT00002569 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCIC Clinical Trials Group Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
NCT00002569 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed North Central Cancer Treatment Group Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
NCT00002569 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed Southwest Oncology Group Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
NCT00002569 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed Radiation Therapy Oncology Group Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lomustine

Condition Name

Condition Name for Lomustine
Intervention Trials
Brain and Central Nervous System Tumors 18
Glioblastoma 16
Glioblastoma Multiforme 12
Lymphoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lomustine
Intervention Trials
Glioblastoma 36
Nervous System Neoplasms 24
Central Nervous System Neoplasms 24
Glioma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lomustine

Trials by Country

Trials by Country for Lomustine
Location Trials
United States 469
Canada 65
Australia 28
United Kingdom 27
Italy 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lomustine
Location Trials
Texas 21
New York 21
Ohio 19
Illinois 18
Pennsylvania 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lomustine

Clinical Trial Phase

Clinical Trial Phase for Lomustine
Clinical Trial Phase Trials
Phase 3 24
Phase 2/Phase 3 6
Phase 2 40
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lomustine
Clinical Trial Phase Trials
Completed 30
Recruiting 13
Active, not recruiting 13
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lomustine

Sponsor Name

Sponsor Name for Lomustine
Sponsor Trials
National Cancer Institute (NCI) 21
European Organisation for Research and Treatment of Cancer - EORTC 7
Children's Oncology Group 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lomustine
Sponsor Trials
Other 91
Industry 33
NIH 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Dow
Mallinckrodt
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.